Boe Technology Group Co., Ltd.

Beijing Boe Display Technology Co., Ltd.

Beijing Kbd Pharmaceuticals Co., Ltd.

Jiangsu Kangbeide Pharmaceuticals Co. Ltd.

Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd.

Shuming Wang

Li Wang

Li Song

Huiyong Xue

Enhong Zhang

Yucheng Lu

Xuying Zhong

Hongguang Du

Feng Qu

Zhihua Sun

Xiaoyan Shi

Shuang Zhang

Yingying Qu

Chun Li

Yifu Chen

Jianhua Huang

Xiaochun Xu

Lingdan Bo

XIaoyan Shi

Hongjun Lian

Guohua Chi

Xiquan Liu

Xiaoling Fan

Zhongren Ding

Guocheng Liu

Provided are a display panel and a display apparatus. The display panel comprises: a first substrate and a second substrate that are arranged opposite each other, wherein a display area and a frame area surrounding the display area are provided between the second substrate and the first substrate; a color resistance structure that is located in the frame area on the side of the second substrate facing the first substrate and surrounds the display area, wherein the color resistance structure comprises a first black matrix and a first color resistance portion arranged in a stacked manner; and a plurality of support bars that surround the display area, wherein each of the support bars fills a space between the color resistance structure and the first substrate.

Display panel comprising a plurality of support bars having ends that sequentially decrease in length in a direction from a frame area to a display area and display apparatus

The present invention relates to the compounds of the formulae (I) and (I-1) and the process for preparing the same, uses of the compounds for the treatment of diseases associated with platelet aggregation and in the manufacture of a medicament for the treatment of diseases associated with platelet aggregation, and relates to a pharmaceutical composition and a pharmaceutical formulation containing the compounds, wherein the definitions of R, R, Rand Rin the formulae are the same as those in the description. 

Ribofuranosyl purine compounds, methods for preparing the same and use thereof

A Rotigotine-containing composition having a matrix mixture system formed from a polyvinylpyrrolidone and a combination of an acrylic pressure-sensitive adhesive with a silicone pressure-sensitive adhesive. The polyvinylpyrrolidone may be present in an amount of about 1-10% by weight in matrix mixture system. The acrylic pressure-sensitive adhesive may be present in an amount of about 1-25% by weight in the matrix mixture system. The silicone pressure-sensitive adhesive may be present in an amount of about 65-98% by weight in the matrix mixture system. The composition further includes 1-40% of Rotigotine on the basis of the total weight of the composition. The composition provides improved properties in the solubility, release and initial penetration level of Rotigotine. Also disclosed is a transdermal patch that includes the Rotigotine-containing composition, as well as methods of manufacturing and using the Rotigotine-containing composition.

Transdermal patch containing Rotigotine

This invention relates to a transdermal patch in the form of a layer complex, comprising a backing layer, a drug-reservoir layer comprising pharmacologically active ingredients and pharmaceutically acceptable adjuvants, and a release liner covering the drug-reservoir layer, characterized in that the drug-reservoir layer comprises isosorbide dinitrate and Bisoprolol at a ratio of 1:3 to 3:1 by weight, as the pharmacologically active ingredients. Animal tests show that said patch can reduce the elevation of T wave of cardiogram, the increase of the level of myocardial enzyme in blood serum, and the extension of the range of myocardial infarction caused by ligating the coronary artery in animals. Results show that said patch exhibits a considerable synergistic effect in the treatment of cardiovascular diseases and has good preventive and therapeutic effects on several adverse events on heart. In addition, the animal tests show that the patch according to the invention has a better pressure-reducing effect than the application of the patch containing only one of isosorbide dinitrate and Bisoprolol, and does not worsen the arrhythmia that is easily caused by the application of the patch containing only isosorbide dinitrate or Bisoprolol.

Transdermal patch containing isosorbide dinitrate and bisoprolol

Growing community of inventors

Beijing, China

Shuming Wang